Literature DB >> 31770652

Prevalence of Errors in Anaphylaxis in Kids (PEAK): A Multicenter Simulation-Based Study.

Tensing Maa1, Daniel J Scherzer2, Ilana Harwayne-Gidansky3, Tali Capua4, David O Kessler5, Jennifer L Trainor6, Priti Jani7, Becky Damazo8, Kamal Abulebda9, Maria Carmen G Diaz10, Rana Sharara-Chami11, Sushant Srinivasan12, Adrian D Zurca13, Ellen S Deutsch14, Elizabeth A Hunt15, Marc Auerbach16.   

Abstract

BACKGROUND: Multi-institutional, international practice variation of pediatric anaphylaxis management by health care providers has not been reported.
OBJECTIVE: To characterize variability in epinephrine administration for pediatric anaphylaxis across institutions, including frequency and types of medication errors.
METHODS: A prospective, observational, study using a standardized in situ simulated anaphylaxis scenario was performed across 28 health care institutions in 6 countries. The on-duty health care team was called for a child (patient simulator) in anaphylaxis. Real medications and supplies were obtained from their actual locations. Demographic data about team members, institutional protocols for anaphylaxis, timing of epinephrine delivery, medication errors, and systems safety issues discovered during the simulation were collected.
RESULTS: Thirty-seven in situ simulations were performed. Anaphylaxis guidelines existed in 41% (15 of 37) of institutions. Teams used a cognitive aid for medication dosing 41% (15 of 37) of the time and 32% (12 of 37) for preparation. Epinephrine autoinjectors were not available in 54% (20 of 37) of institutions and were used in only 14% (5 of 37) of simulations. Median time to epinephrine administration was 95 seconds (interquartile range, 77-252) for epinephrine autoinjector and 263 seconds (interquartile range, 146-407.5) for manually prepared epinephrine (P = .12). At least 1 medication error occurred in 68% (25 of 37) of simulations. Nursing experience with epinephrine administration for anaphylaxis was associated with fewer preparation (P = .04) and administration (P = .01) errors. Latent safety threats were reported by 30% (11 of 37) of institutions, and more than half of these (6 of 11) involved a cognitive aid.
CONCLUSIONS: A multicenter, international study of simulated pediatric anaphylaxis reveals (1) variation in management between institutions in the use of protocols, cognitive aids, and medication formularies, (2) frequent errors involving epinephrine, and (3) latent safety threats related to cognitive aids among multiple sites.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; Autoinjector; Epinephrine; Medication error; Simulation

Mesh:

Substances:

Year:  2019        PMID: 31770652     DOI: 10.1016/j.jaip.2019.11.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  4 in total

Review 1.  Recent Advances in Simulation for Pediatric Critical Care Medicine.

Authors:  Ilana Harwayne-Gidansky; Rahul Panesar; Tensing Maa
Journal:  Curr Pediatr Rep       Date:  2020-08-28

2.  Adhering to Social Distancing Rules Using a "Split Patient" Model With Rapid Cycle Deliberate Practice in Pediatric High-Fidelity Simulations.

Authors:  Rahul S Panesar; Erin Hulfish; Ilana Harwayne-Gidansky
Journal:  Cureus       Date:  2021-03-25

3.  What is new in anaphylaxis?

Authors:  Alberto Martelli; Rosario Ippolito; Martina Votto; Maria De Filippo; Ilaria Brambilla; Mauro Calvani; Fabio Cardinale; Elena Chiappini; Marzia Duse; Sara Manti; Gian Luigi Marseglia; Carlo Caffarelli; Claudio Cravidi; Michele Miraglia Del Giudice; Maria Angela Tosca
Journal:  Acta Biomed       Date:  2020-09-15

4.  Improving Safety Recommendations Before Implementation: A Simulation-Based Event Analysis to Optimize Interventions Designed to Prevent Recurrence of Adverse Events.

Authors:  Mélissa Langevin; Natalie Ward; Colleen Fitzgibbons; Christa Ramsay; Melanie Hogue; Anna-Theresa Lobos
Journal:  Simul Healthc       Date:  2022-02-01       Impact factor: 1.929

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.